Heart failure with preserved ejection fraction based on aging and comorbidities

被引：0
作者：
Ying Lin
Shihui Fu
Yao Yao
Yulong Li
Yali Zhao
Leiming Luo
机构：
[1] Hainan Hospital of Chinese People’s Liberation Army General Hospital,Department of Cardiology
[2] Chinese People’s Liberation Army General Hospital,Department of Geriatric Cardiology
[3] Medical School of Duke University,Centre for the Study of Ageing and Human Development and Geriatrics Division
[4] National School of Development,Centre for Healthy Ageing and Development Studies
[5] Peking University,Central Laboratory
[6] Hainan Hospital of Chinese People’s Liberation Army General Hospital,undefined
来源：
Journal of Translational Medicine | / 19卷
关键词：
Aging; Comorbidities; Diagnosis; Heart failure with preserved ejection fraction; Treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Heart failure (HF) with preserved ejection fraction (HFpEF) is a leading cause of hospitalizations and mortality when diagnosed at the age of ≥ 65 years. HFpEF represents multifactorial and multisystemic syndrome and has different pathophysiology and phenotypes. Its diagnosis is difficult to be established based on left ventricular ejection fraction and may benefit from individually tailored approaches, underlying age-related changes and frequent comorbidities. Compared with the rapid development in the treatment of heart failure with reduced ejection fraction, HFpEF presents a great challenge and needs to be addressed considering the failure of HF drugs to improve its outcomes. Further extensive studies on the relationships between HFpEF, aging, and comorbidities in carefully phenotyped HFpEF subgroups may help understand the biology, diagnosis, and treatment of HFpEF. The current review summarized the diagnostic and therapeutic development of HFpEF based on the complex relationships between aging, comorbidities, and HFpEF.
引用
收藏
相关论文
共 377 条
  • [111] Yancy CW(2019)Relationship between drug application and mortality rate in Chinese older coronary artery disease/chronic heart failure patients with and without low glomerular filtration rate BMC Pharmacol Toxicol 20 44-1277
  • [112] Taqueti VR(2013)Association between epicardial fat thickness and weight homeostasis hormones in patients with noncachectic heart failure Angiology 64 173-2573
  • [113] Hussain N(2012)Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial Lancet 380 1387-17
  • [114] Shah AM(2018)Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure J Biol Eng 12 2-791
  • [115] Solomon SD(2018)Brain natriuretic peptide and its biochemical, analytical, and clinical issues in heart failure: a narrative review Front Physiol 9 692-1771
  • [116] Pieske B(2003)Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial Lancet 362 777-217
  • [117] Haykowsky M(2014)New insights in (inter) cellular mechanisms by heart failure with preserved ejection fraction Curr Heart Fail Rep 11 436-264
  • [118] Kouba EJ(2015)Isosorbide mononitrate in heart failure with preserved ejection fraction N Engl J Med 373 2314-435
  • [119] Brubaker PH(2018)Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: the INDIE-HFpEF randomized clinical trial JAMA 320 1764-855
  • [120] Nicklas BJ(2009)Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure Basic Res Cardiol 104 499-146
78910111213141516